David A. Siegel Avalo Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.0 - $10.45 $629,700 - $2.19 Million	-209,900 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$7.57 - $21.72 $2 Million - $5.74 Million	-264,100 Reduced 55.72%	209,900 $152,000
Q4 2021 Feb 14, 2022	SELL	$19.68 - $28.68 $6.44 Million - $9.39 Million	-327,300 Reduced 40.85%	474,000 $806,000
Q3 2021 Nov 15, 2021	BUY	$26.16 - $40.68 $21 Million - $32.6 Million	801,300 New	801,300 $1.75 Million

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $115M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.